Gradual reduction in rRNA transcription triggers p53 acetylation and apoptosis via MYBBP1A

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kumazawa, Takuya ^a,b   Nishimura, Kazuho ^a   Katagiri, Naohiro ^a   Hashimoto, Sayaka ^a   Hayashi, Yuki ^a   Kimura, Keiji ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MYBBP1A PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PROTEIN P53; RIBOSOMAL PROTEIN L11; RIBOSOME PROTEIN; RIBOSOME RNA;

ACETYLATION; APOPTOSIS; BIOLOGICAL MODEL; CELL NUCLEUS; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PROTEIN TRANSPORT; RNA INTERFERENCE; TUMOR CELL LINE;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PROTEIN TRANSPORT; RIBOSOMAL PROTEINS; RNA INTERFERENCE; RNA, RIBOSOMAL; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930622987     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10854     Document Type: Article

References (60)

1. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009).
2. Lee, J. T. & Gu, W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17, 86-92 (2010).
3. Olson, M. O. Sensing cellular stress: another new function for the nucleolus? Sci. STKE 2004, pe10 (2004).
4. Appella, E. & Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. FEBS 268, 2764-2772 (2001).
5. Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4, 793-805 (2004).
6. Brooks, C. L. & Gu, W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15, 164-171 (2003).
7. Carter, S. & Vousden, K. H. Modifications of p53: competing for the lysines. Curr. Opin. Genet. Dev. 19, 18-24 (2009).
8. Vousden, K. H. & Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283 (2007).
9. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
10. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
11. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001).
12. Pawlowski, J. & Kraft, A. S. Bax-induced apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 97, 529-531 (2000).
13. Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058 (2000).
14. Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862 (2000).
15. Contente, A., Dittmer, A., Koch, M. C., Roth, J. & Dobbelstein, M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30, 315-320 (2002).
16. Weinberg, R. L., Veprintsev, D. B., Bycroft, M. & Fersht, A. R. Comparative binding of p53 to its promoter and DNA recognition elements. J. Mol. Biol. 348, 589-596 (2005).
17. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
18. Luo, J. et al. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 101, 2259-2264 (2004).
19. Tang, Y., Luo, J., Zhang, W. & Gu, W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24, 827-839 (2006).
20. Sykes, S. M. et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24, 841-851 (2006).
21. Taira, N., Nihira, K., Yamaguchi, T., Miki, Y. & Yoshida, K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol. Cell 25, 725-738 (2007).
22. D'Orazi, G. et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4, 11-19 (2002).
23. Beckerman, R. & Prives, C. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2, a000935 (2010).
24. Espinosa, J. M. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27, 4013-4023 (2008).
25. Vousden, K. H. & Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell 137, 413-431 (2009).
26. Lai, P. B., Chi, T. Y. & Chen, G. G. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 12, 387-393 (2007).
27. Tanaka, T., Ohkubo, S., Tatsuno, I. & Prives, C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 130, 638-650 (2007).
28. Boulon, S., Westman, B. J., Hutten, S., Boisvert, F. M. & Lamond, A. I. The nucleolus under stress. Mol. Cell 40, 216-227 (2010).
29. Rubbi, C. P. & Milner, J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22, 6068-6077 (2003).
30. Zhang, Y. & Lu, H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 16, 369-377 (2009).
31. Lohrum, M. A., Ludwig, R. L., Kubbutat, M. H., Hanlon, M. & Vousden, K. H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-587 (2003).
32. Marechal, V., Elenbaas, B., Piette, J., Nicolas, J. C. & Levine, A. J. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 14, 7414-7420 (1994).
33. Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U.S.A. 95, 8292-8297 (1998).
34. Pomerantz, J. et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723 (1998).
35. Dai, M. S. & Lu, H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475-44482 (2004).
36. Dai, M. S. et al. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 24, 7654-7668 (2004).
37. Jin, A., Itahana, K., O'Keefe, K. & Zhang, Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24, 7669-7680 (2004).
38. Kurki, S. et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5, 465-475 (2004).
39. Saxena, A., Rorie, C. J., Dimitrova, D., Daniely, Y. & Borowiec, J. A. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 25, 7274-7288 (2006).
40. Chen, Z., Knutson, E., Wang, S., Martinez, L. A. & Albrecht, T. Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J. Biol. Chem. 282, 29284-29295 (2007).
41. Zhu, Y. et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell 35, 316-326 (2009).
42. Yuan, X. et al. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 19, 77-87 (2005).
43. Donati, G., Peddigari, S., Mercer, C. A. & Thomas, G. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep. 4, 87-98 (2013).
44. Li, M. & Gu, W. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol. Cell 43, 1023-1032 (2011).
45. Sloan, K. E., Bohnsack, M. T. & Watkins, N. J. The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress. Cell Rep. 5, 237-247 (2013).
46. Nishimura, K. et al. Perturbation of Ribosome Biogenesis Drives Cells into Senescence through 5S RNP-Mediated p53 Activation. Cell Rep. 10, 1310-1323 (2015).
47. Kuroda, T. et al. RNA content in the nucleolus alters p53 acetylation via MYBBP1A. EMBO J. 30, 1054-1066 (2011).
48. Kumazawa, T. et al. Novel nucleolar pathway connecting intracellular energy status with p53 activation. J. Biol. Chem. 286, 20861-20869 (2011).
49. Ono, W. et al. Nucleolar protein, Myb-binding protein 1A, specifically binds to nonacetylated p53 and efficiently promotes transcriptional activation. Biochem. Biophys. Res. Commun. 434, 659-663 (2013).
50. Ono, W. et al. The nucleolar protein Myb-binding protein 1A (MYBBP1A) enhances p53 tetramerization and acetylation in response to nucleolar disruption. J. Biol. Chem. 289, 4928-4940 (2014).
51. Burger, K. et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem. 285, 12416-12425 (2010).
52. Holzel, M. et al. Defects in 18 S or 28 S rRNA processing activate the p53 pathway. J. Biol. Chem. 285, 6364-6370 (2010).
53. McMahon, M., Ayllon, V., Panov, K. I. & O'Connor, R. Ribosomal 18 S RNA processing by the IGF-I-responsive WDR3 protein is integrated with p53 function in cancer cell proliferation. J. Biol. Chem. 285, 18309-18318 (2010).
54. Castle, C. D., Cassimere, E. K., Lee, J. & Denicourt, C. Las1L is a nucleolar protein required for cell proliferation and ribosome biogenesis. Mol. Cell. Biol. 30, 4404-4414 (2010).
55. Schlereth, K. et al. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 38, 356-368 (2010).
56. Schlereth, K., Charles, J. P., Bretz, A. C. & Stiewe, T. Life or death: p53-induced apoptosis requires DNA binding cooperativity. Cell Cycle 9, 4068-4076 (2010).
57. Hoppe, S. et al. AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc. Natl. Acad. Sci. U.S.A. 106, 17781-17786 (2009).
58. Kruhlak, M. et al. The ATM repair pathway inhibits RNA polymerase I transcription in response to chromosome breaks. Nature 447, 730-734 (2007).
59. Andersen, J. S. et al. Nucleolar proteome dynamics. Nature 433, 77-83 (2005).
60. Kaeser, M. D. & Iggo, R. D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 99, 95-100 (2002).